ArticleDiscover oncology2026
Sex-related differences in pathological characteristics of colorectal cancer: a retrospective study.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeColorectal cancer (CRC) exhibits substantial sex-related differences in incidence, prognosis, and clinicopathological features. However, existing evidence on these disparities remains limited and inconclusive. This study aimed to investigate sex-specific patterns in tumor differentiation, metastasis, and mismatch repair (MMR) status, and to determine whether these associations persist after adjustment for clinicopathological covariates.
methodsA retrospective cohort study was conducted in 2,912 patients who underwent surgery for CRC at West China Hospital between November 2008 and June 2023. Sex differences were assessed across subgroups stratified by tumor differentiation grade, metastatic status, and age at onset. Three multivariable Firth penalized logistic regression models were constructed to assess whether sex remained an independent predictor of metastasis, deficient MMR (dMMR), and poor differentiation (G3) after adjustment for age, body mass index (BMI), stage, tumor location, and relevant molecular markers.
resultsSignificant sex-related differences were observed in tumor differentiation, metastasis, and MMR status. Female patients had higher rates of poorly differentiated (G3) tumors, dMMR, and metastasis. However, these differences were markedly heterogeneous and were most evident in moderately differentiated (G2) tumors, late-onset CRC, and non-metastatic disease, whereas no significant sex differences were identified in early-onset disease. In multivariable analysis, female sex remained an independent predictor of metastasis (adjusted OR 1.36, 95% CI 1.04-1.79, P = 0.024), but not of dMMR (adjusted OR 1.28, P = 0.108) or G3 differentiation (adjusted OR 1.15, P = 0.146), suggesting that the latter associations were largely explained by tumor location.
conclusionSex-related differences in CRC are context-dependent and vary according to tumor differentiation, metastatic status, and age at diagnosis. The higher metastatic risk observed in female patients appears to be an independent association, whereas differences in dMMR and tumor grade mainly reflect the greater prevalence of right-sided tumors in women. These findings support the incorporation of sex as a biological variable in metastatic risk stratification, while highlighting the importance of accounting for anatomical confounding when interpreting molecular and histological sex differences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.